Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Inhibikase Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −2 vs. Q1 2022
- Shares held
- 3.35M
- −924.6K (−21.6%) vs. Q1 2022
- Total value
- $2.49M
- −$3.84M (−60.7%) vs. Q1 2022
- New holders
- 4
- 8 more added
- Sold out
- 6
- 4 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 133 | $0 | 0.00% | +11+9.0% | Added |
| Citigroup Inc | 500 | $0 | 0.00% | +500 | New |
| Morgan Stanley | 10,000 | $7.00K | 0.00% | +10,000 | New |
| Shay Capital LLC | 10,708 | $8.00K | 0.00% | −9,292−46.5% | Reduced |
| Warberg Asset Management LLC | 14,493 | $11.0K | 0.00% | +1,000+7.4% | Added |
| Tower Research Capital LLC (TRC) | 16,022 | $12.0K | 0.00% | +14,425+903.3% | Added |
| K.J. Harrison & Partners Inc | 18,300 | $14.0K | 0.00% | +7,000+61.9% | Added |
| Blair William & Co | 25,000 | $19.0K | 0.00% | +25,000 | New |
| Northern Trust Corp | 28,872 | $21.0K | 0.00% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 39,312 | $29.0K | 0.00% | −268−0.7% | Reduced |
| State Street Corp | 60,500 | $45.0K | 0.00% | +2,400+4.1% | Added |
| Retirement Planning Co of New England, Inc. | 64,606 | $47.0K | 0.03% | −51,796−44.5% | Reduced |
| Koshinski Asset Management, Inc. | 65,377 | $49.0K | 0.00% | +65,377 | New |
| Geode Capital Management, LLC | 89,226 | $66.0K | 0.00% | +5,017+6.0% | Added |
| Zeke Capital Advisors, LLC | 93,800 | $70.0K | 0.00% | 00.0% | Unchanged |
| Redmond Asset Management, LLC | 122,682 | $91.0K | 0.03% | 00.0% | Unchanged |
| Hamilton Lane Advisors LLC | 165,635 | $123.0K | 0.05% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 221,900 | $165.0K | 0.00% | +33,431+17.7% | Added |
| Antara Capital LP | 403,000 | $299.0K | 0.03% | +100,000+33.0% | Added |
| FMR LLC | 433,300 | $322.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 530,098 | $394.0K | 0.00% | 00.0% | Unchanged |
| ACT Capital Management, LLC | 937,500 | $696.0K | 0.97% | −139,000−12.9% | Reduced |
| Kepos Capital LP | 0 | $0 | 0.00% | −700,000−100.0% | Sold out |
| Lynwood Capital Management Inc. | 0 | $0 | 0.00% | −120,000−100.0% | Sold out |
| Sabby Management, LLC | 0 | $0 | 0.00% | −99,000−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −51,497−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −12,756−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,112−100.0% | Sold out |